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Tumor cells metastasize to distant organs through
genetic andepigenetic alterations, including changes
in microRNA (miR) expression. Here we find miR-22
triggers epithelial-mesenchymal transition (EMT),
enhances invasiveness and promotes metastasis
in mouse xenografts. In a conditional mammary
gland-specific transgenic (TG) mouse model, we
show that miR-22 enhances mammary gland side-
branching, expands the stem cell compartment, and
promotes tumor development. Critically, miR-22
promotes aggressive metastatic disease in MMTV-
miR-22 TG mice, as well as compound MMTV-neu
or -PyVT-miR-22 TG mice. We demonstrate that
miR-22 exerts its metastatic potential by silencing
antimetastatic miR-200 through direct targeting of
the TET (Ten eleven translocation) family ofmethylcy-
tosine dioxygenases, thereby inhibiting demethyla-
tion of the mir-200 promoter. Finally, we show that
miR-22 overexpression correlates with poor clinical
outcomes and silencing of the TET-miR-200 axis in
patients. Taken together, our findings implicate
miR-22 as a crucial epigenetic modifier and pro-
moter of EMT and breast cancer stemness toward
metastasis.INTRODUCTION
Metastasis remains one of most complex and challenging
problems of contemporary oncology. During metastatic dissem-ination, a cancer cell from a primary tumor executes a multistep
process: intravasation, survival in the circulation, extravasa-
tion, micrometastases, and colonization (Fidler, 2003). Recent
studies have demonstrated that as tumors progress, genetic
and epigenetic mechanisms may result in the emergence of a
self-renewing metastatic cancer stem cell (CSC), also referred
to as cancer initiating cell (CIC) (Ito et al., 2009; Visvader and Lin-
deman, 2008). This metastatic CSC eventually enters the blood
stream and seeds a secondary tumor in a distinct organ.
CSCs/CICs are thought to exist in primary tumors from the
very early stages of tumorigenesis and may be the oncogenic
derivatives of normal-tissue stem or progenitor cells.
CSCs may also arise as a consequence of the epithelial-
mesenchymal transition (EMT), a developmental program that
is instrumental to the acquisition of stemness by nontransformed
and tumor cells (Chaffer and Weinberg, 2011; Gupta and Mas-
sague´, 2006). Although much progress has been garnered in
elucidating the molecular pathways that trigger EMT and metas-
tasis, a number of key mechanistic gaps remain to be explained,
suggesting that critical players in the process have yet to be
identified.
MicroRNAs (miRNAs) are small noncoding RNAs that lead to
silencing of their cognate target genes by either degrading
mRNA molecules or inhibiting their translation (Bartel, 2004).
Indeed, miRNAs have been implicated in the regulation of a
variety of cellular processes, including stemness and metas-
tasis, implying that they can function either as oncogenes or
tumor suppressors (Calin et al., 2005; He et al., 2005; Ma et al.,
2007). For instance, the miR-200 family members (miR-200s)
are known as tumor suppressive miRNAs that regulate the
EMT and control stemness by directly targeting transcriptional
repressor Zeb1/2 (zinc finger E-box-binding homeobox 1/2)
and polycomb repressor complex proteins, such as Bmi1
(B lymphoma Mo-MLV insertion region 1 homolog) and Suz12Cell 154, 311–324, July 18, 2013 ª2013 Elsevier Inc. 311
(suppressor of zeste 12 homolog) (Iliopoulos et al., 2010; Shi-
mono et al., 2009). Interestingly, miR-200s are downregulated
in different types of cancer (Adam et al., 2009; Bendoraite
et al., 2010; Olson et al., 2009), and they are specifically downre-
gulated in breast CSCs in comparison with nontumorigenic can-
cer cells (Shimono et al., 2009).
The selective deregulation of miRNA gene expression may be
due to deletion, amplification, or mutations targeting themiRNAs
themselves, as well as deregulation of transcription factors and
epigenetic regulators targeting the genes encoding them (Brev-
ing and Esquela-Kerscher, 2010; Calin et al., 2005). In particular,
although promoter hypermethylation and associated inactivation
of tumor suppressor genes is an established molecular hallmark
of human cancer (Esteller, 2008; Jones and Baylin, 2007), this
epigenetic lesion has recently been extended to the DNAmethyl-
ation-mediated silencing of miRNAs (Lujambio et al., 2007; Saito
et al., 2006; Toyota et al., 2008). DNA methylation can be herit-
ably maintained across cell division, but can also be reversibly/
dynamically altered to establish new epigenetic programs.
The recent discovery of members of the TET (Ten eleven trans-
location) family that can specifically modify DNA by hydroxylat-
ing 5-methylcytosine (5mC) may explain how cells can erase
existing methylation marks (Ito et al., 2010; Ko et al., 2010; Tahi-
liani et al., 2009). Within the TET family of proteins, TET1, TET2,
and TET3 have been shown to convert 5mC to 5-hydroxyme-
thylcytosine (5hmC), whereas TET2-inactivating deletion and
mutations have been frequently observed in hematopoietic
malignancies (Ko et al., 2010; Tahiliani et al., 2009). Notably,
the level of 5hmC, so tightly associated with TET gene expres-
sion, is increased in differentiated cells and is profoundly
reduced in many types of tumors, identifying 5hmC as a
biomarker associated with tumor development (Haffner et al.,
2011; Yang et al., 2013).
Here, we show that miR-22 triggers enhanced mammary
gland hyperplasia as well as a marked expansion of the mam-
mary stem cell compartment, hence triggering tumor initiation.
Importantly, we demonstrate that miR-22 promotes themetasta-
tic process and EMT through its ability to repress the expression
of miR-200s as well as 5hmC by directly targeting members of
the TET family.
RESULTS
miR-22 Promotes EMT and Tumor Invasion
and Metastasis
To investigate the potential oncogenic effects of miR-22 expres-
sion, we first transduced a retroviral vector encoding the human
mir-22 gene into immortalized human breast epithelial cells,
HMEC and MCF-10A, and unexpectedly found that ectopic
expression of miR-22 results in an increased cell motility in an
in vitro assay (Figure S1A, available online, and data not shown).
A dramatic morphological change was also observed in miR-22-
overexpressing cells, in which the typical cobblestone-like
appearance of normal epithelium was replaced by a spindle-
like, fibroblastic morphology (Figure S1B). In agreement with
these observations, we found that miR-22-overexpressing cells
displayed a silenced expression of the key epithelial marker
E-cadherin, and the upregulations of the mesenchymal markers312 Cell 154, 311–324, July 18, 2013 ª2013 Elsevier Inc.N-cadherin, vimentin, and fibronectin (Figures 1A, 1B and S1C).
The EMT is known to be a central mechanism responsible for
invasiveness and metastasis of breast cancer and is also asso-
ciated with normal and malignant mammary stem cell function
(Gupta and Massague´, 2006). Therefore we speculated that
miR-22 could also induce stemness. Noticeably, miR-22 expres-
sion increased the ability of MCF-10A cells to develop into mam-
mosphere structures, suggesting that miR-22 triggers EMT and
stemness (Figures 1C, S1D, and S1E).
To determine whether miR-22 could induce similar effects
in vivo, we next established a xenograft model using the nonme-
tastatic breast cancer cell line MCF-7. We used a miR-22/GFP-
expressing retroviral vector to transduce MCF-7 cells and
implanted them into cleared mammary fat pads of Nu/Nu immu-
nodeficient mice (Figures S1F and S1G). Within 3 weeks of injec-
tion, recipient mice developed macroscopic GFP+ tumors with
expansive and infiltrative growth patterns; by 12 weeks, in two
of six cases massive lymphatic invasions were also observed
in the adjacent normal breast tissues (Figure 1D). In comparison,
at the same time point, MCF-7 control tumors were strictly
noninvasive. The distribution, but not the total number of Ki67+
(proliferating) cells in miR-22-overexpressing tumors, was also
distinct from that seen in the control tumors: in the former, large
necrotic centers were apparent and Ki67+ cells were enriched in
the highly vascularized invasive regions, whereas in the latter the
vascularization was poor and the Ki67+ cells were evenly distrib-
uted (Figures 1E and S1F). Furthermore, the vessels associated
with the invasive regions of miR-22-overexpressing tumors were
observed not only in the stroma (peritumoral), but also within the
epithelial tumor masses (intratumoral) (Figures 1E and 1F).
To determine whether miR-22-overexpressing MCF-7 cells
could metastasize to distant sites, we undertook a detailed path-
ological analysis of the major organs of our implanted recipients.
Strikingly, six out of six mice that received the orthotopic implan-
tation of miR-22-overexpressing cells displayed numerous lung
metastases that were readily detectable by both GFP fluores-
cence and histological analysis (Figure 1G). These clusters of
cells were stained positive for Ki67 and estrogen receptor a
(ERa), and negative for thyroid transcription factor 1 (TTF1; a
marker of primary lung adenocarcinoma), further confirming their
origin (Figure 1H). In contrast, no metastases were found in con-
trol animals (Figure 1I). Taken together, our data suggest that
miR-22 can contribute to cell proliferation, invasion, and angio-
genesis, and, importantly, can impart metastatic properties on
otherwise nonmetastatic cells.
miR-22 Increases Mammary Stem Population and
Promotes Tumorigenesis and Metastasis In Vivo In
Transgenic Mice
Although these cell line studies were highly suggestive, we
attempted to confirm and expand on our findings using a condi-
tional transgenic mouse model. To this end, we engineered mice
that harbored within their Collagen A1 locus the CAGGS pro-
moter and the mir-22 genomic sequence separated by a LoxP
flanked transcriptional STOP cassette (hereafter referred to as
miR-22F/+) (Figures 2A and 2B). By crossing these mice with
mice that express the Cre recombinase under the control of
the mouse mammary tumor virus promoter (MMTV-Cre), we
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Figure 1. miR-22 Enhances EMT and Tumor
Invasion and Metastasis
(A and B) MCF-7 (A) or MCF-10A (B) cells infected
with the miR-22 expressing or empty vector were
subjected to immunofluorescence (A) and western
blot (B) analyses for the indicated proteins. Scale
bars, 20 mm.
(C) Replating efficiency of mammospheres derived
from MCF-10A cells expressing miR-22 was
measured. The number of mammospheres per
1,000-plated cells in each culture was then quan-
tified. The data are represented as mean ± SD
from three independent experiments.
(D) H&E-stained sections of primary mammary
tumors formed byMCF-7 cells expressing miR-22,
at 12 weeks after orthotopic transplantation.
Arrows indicate areas of lymphatic invasion. Scale
bars, 50 mm.
(E and F) Ki67- and MECA-32-stained sections of
primary mammary tumors formed by MCF-7 cells
expressing miR-22 (E). Arrows indicate tumor cells
within a vessel. Scale bars, 50 mm. The quantifi-
cation of vessel numbers (using MECA-32–stained
sections) at the center and the edge of the primary
mammary tumors is also shown (F). The data are
represented as mean ± SD (n = 6).
(G) GFP images (left) and H&E staining (right) of
lungs isolated from mice that at 12 weeks after
transplantation received orthotopic injection of
MCF-7 cells expressing miR-22. Arrow indicates
clusters of metastatic cells. Scale bars, 100 mm.
(H and I) H&E-, Ki67-, ERa-, and TTF1-stained
sections of lungs isolated from mice that at
12 weeks after transplantation received orthotopic
injection of MCF-7 cells expressing miR-22 (H).
Scale bars, 50 mm. The number of lung micro-
metastases (micromets) per section in individual
mice was also quantified (I). The data are repre-
sented as mean ± SD (n = 6).
See Figures S1A–S1G.could induce targeted expression of miR-22 in the mammary
glands. Real-time quantitative PCR and northern blot analyses
revealed that miR-22 expression was increased 2- to 3-fold in
miR-22F/+;MMTV-Cre mice compared to littermate controls
(Figure 2C).
Noticeably, in agreement with our observation in cell line
studies, epithelial cell migration and western blot analyses in
breast epithelium obtained frommiR-22F/+;MMTV-Cre and con-
trol mice revealed a marked increase in EMT features in cells
from the transgenic animals at young age (Figures S1H and
S1I). Strikingly, by 7 weeks of age, miR-22 transgenic mice
demonstrated an increased ductal side-branching (p < 0.001,
Figure 2D) and higher numbers of mammary stem cells (MSCs;
defined as CD24highCD49fhigh) (p = 0.001, Figure 2E), and cells
from these mice displayed an increased ability to form mammo-
spheres—3D structures in culture (p = 0.019, Figure S1J).Cell 154, 311–In agreement with these findings, it has
been previously reported that miR-22
is highly expressed in mouse mammary
progenitor cells (Ibarra et al., 2007).Importantly, limiting dilution transplantation experiments with
CD24highCD49fhigh MSCs revealed that the increase in lobu-
loalveolar structures in miR-22 transgenic mice directly relates
to MSCs, but not to aberrant hormonal signaling during the oes-
trus cycle (Figures 2F and 2G).
Next, we performed a long-term evaluation of spontaneous
mammary tumorigenesis and metastasis in vivo in miR-22
transgenic mice. Remarkably, miR-22 overexpression in mice
resulted in a progressive decrease in the disease-free survival
rate at the age of 8 to 24 months (n = 11) (p = 0.0024, Figure 3A).
Diffuse alveolar and ductal hyperplasia, focal mammary ductal
ectasia, impaction of thick materials, and, more importantly,
focal ductal carcinomas were observed in virgin female
miR-22F/+;MMTV-Cre mice (at approximately 60% incidence),
whereas no hyperplasia nor tumor was observed in control mice
(Figure 3B). Noticeably, miR-22F/+;MMTV-Cre mice displayed324, July 18, 2013 ª2013 Elsevier Inc. 313
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B A Figure 2. miR-22 IncreasesMammary Gland
Side-Branching and Stemness In Vivo in
Transgenic Mice
(A) Schematic representation of the strategy for
generation of floxed miR-22 mouse embryonic
stem cells. Red arrows indicate the positions of
primers used for genotyping themiR-22 transgenic
mice. Blue line indicates the position of probe for
the Southern blot analysis. The F1 floxed miR-22
founder mice were bred to MMTV-Cre strain to
delete LoxP site.
(B) Genomic DNAs were isolated from the tails of
miR-22-LoxP mice were digested by Spe I and
subjected to Southern blot analysis.
(C) Total RNAs isolated from mammary gland
tissues of miR-22F/+;MMTV-Cre mice were
subjected to real-time qPCR (left) or northern
blot analysis (right) to evaluate miR-22 exp-
ression. The data are represented as mean ± SD
(n = 4).
(D) Whole-mount analyses were conducted
on 7-week-old miR-22F/+;MMTV-Cre mice and
MMTV-Cre littermates (left) and the number of
mammary gland side-branches was quantified
(right). Scale bars, 500 mm. The data are repre-
sented as mean ± SD (n = 3).
(E) Distribution of CD45negCD31negCD140aneg
Ter119neg mouse mammary cells according to
their expression of CD24 and CD49f were
analyzed on 7-week-old miR-22F/+;MMTV-Cre
mice and littermate controls (left). MSCs accord-
ing to their expression of CD24highCD49high in
Lineagenegative (middle) or total mammary epithe-
lial cells (right) were quantified by a flow cyto-
metric analysis. The data are represented as
mean ± SD (n = 4).
(F and G) Schematic representation of limi-
ting dilution transplantation experiments with
CD24highCD49fhigh MSCs (F). A total of 3 3 102,
1 3 103, or 1.2 3 104 LinnegCD24high
CD49high MSCs isolated from 7-week-old
miR-22F/+;MMTV-Cre mice and littermate con-
trols were injected into the cleared fat-pad of
3-week-old FVB/NJ female mice and whole-mount analyses were then conducted at 6 weeks after injection (G). Representative images of mammary
gland side-branches are shown on the left. The resulting data were also analyzed by Chi-square test (right).
See Figures S1H–S1J.EMT-related breast tumor phenotypes (Figure 3C), and their
primary tumors represented both luminal (cytokeratin-8-positive
and cytokeratin-14-negative) andmixed luminal-basal (cytokera-
tin-8-positive and cytokeratin-14-positive) cell fates, although the
intensities of positivity of cytokeratin 8 are partially weaker than
those of normal mammary glands (Figure S2A). Most strikingly,
postpregnantmiR-22F/+;MMTV-Cremice developed lungmetas-
tases at 8 to 10 months of age (at 100% incidence) mostly in the
peri-bronchiolar lymphatic space (n = 3) (Figures 3D and 3E).
In addition, by utilizing a series of genetically engineered
mouse models, we further explored whether miR-22 can pro-
mote breast cancer and metastasis in vivo. As MMTV-PyVT
transgenic mice are known to develop multifocal mammary
tumors that spontaneously metastasize to the lung (Guy et al.,
1992a), we first crossed these mice with our miR-22F/+;MMTV-
Cre mice and analyzed the resultant compound mutants for
development of primary tumors and lung metastases. Although314 Cell 154, 311–324, July 18, 2013 ª2013 Elsevier Inc.miR-22 overexpression had no significant effect on the develop-
ment or size of primary mammary gland lesions in this model, the
penetrance of metastatic cancer, analyzed at different time
points (8 to 12 weeks), was increased in MMTV-PyVT;miR-
22F/+;MMTV-Cre mice when compared toMMTV-PyVT controls
(Figures S2B and S2C).
AsMMTV-PyVT animals are difficult to compare precisely due
to their very early onset of lung metastases, we next generated
and analyzed MMTV-neu;miR-22F/+;MMTV-Cre mice, taking
advantage of the fact thatMMTV-neumice express unactivated
neu (c-ErbB2) and show less aggressive mammary tumors and
lung metastases (Guy et al., 1992b). Remarkably, the devel-
opment of primary mammary gland lesions as well as the
incidence of lung metastases was significantly increased in
MMTV-neu;miR-22F/+;MMTV-Cre mice, by 19 months of age,
when compared to MMTV-neu controls (Figures 3F and S2D).
Importantly, MMTV-neu;miR-22F/+;MMTV-Cre mice exhibited
A B
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Figure 3. miR-22 Induces Mammary Tumori-
genesis and Metastasis In Vivo in Transgenic
Mice
(A) Cumulative disease-free survival analysis. A
statistically significant decrease in lifespan for the
miR-22F/+;MMTV-Cre cohort was found compared
with the MMTV-Cre cohort (p = 0.0024, n = 11).
(B) H&E-stained sections of diffuse alveolar and
ductal hyperplasia isolated from 12-month-old
miR-22F/+;MMTV-Cre mice. Scale bars, 200 mm.
(C) Lysates from mammary tumors of miR-
22F/+;MMTV-Cre mice were subjected to western
blot analysis for the indicated proteins.
(D and E) H&E-stained sections of primary mam-
mary tumors and lungs isolated from 8-month-old
postpregnant miR-22F/+;MMTV-Cre mice (D).
Arrows indicate clusters of metastatic cells in the
lung. Scale bars, 200 mm. H&E- and Ki67-stained
sections of lungs isolated from miR-22F/+;MMTV-
Cre mice are also shown (E). Scale bars, 200 mm.
(F) The incidence of metastases to the lung in
MMTV-neu;miR-22F/+;MMTV-Cre (represented as
miR-22F/+;MMTV-neu) and MMTV-neu littermates
(8 to 16 months old) was quantified.
(G) Lysates from mammary tumors of miR-
22F/+;MMTV-neu were subjected to western blot
analysis for the indicated proteins.
(H and I) H&E-stained sections of the lungs isolated
from miR-22F/+;MMTV-neu mice and littermate
controls (H). Arrows indicate clusters of metastatic
cells in the lung. Scale bars, 200 mm. H&E-, Ki67-,
and ErbB2-stained sections of lungs isolated from
miR-22F/+;MMTV-neu mice are also shown (I).
Scale bars, 200 mm.
See Figure S2.EMT-related breast tumor phenotypes (Figures 3G and
S2E). Interestingly, a significant number of MMTV-neu;miR-
22F/+;MMTV-Cre breast tumorswere both cytokeratin-8-positive
andcytokeratin-14-positive,whereasMMTV-neucontrol primary
tumorswere cytokeratin-8-positive andcytokeratin-14-negative,
suggesting thatmiR-22 inducesa significant luminal-to-basal cell
fate change inbreast tumor cells in thepresenceofneuoncogene
insult (Figure S2F). Notably, MMTV-neu;miR-22F/+;MMTV-Cre
breast tumors also presented a significant increase in the popu-
lation of CD24posCD90pos CSCs compared toMMTV-neu control
tumors (Figure S2G and Malanchi et al., 2012). Finally, the pene-
tranceofmetastases to the lungweregreatly increased inMMTV-
neu;miR-22F/+;MMTV-Cre mice when compared to MMTV-neu
control mice of the same age (Figures 3H and 3I).
Taken together, these data indicate that miR-22 plays a crucial
role in breast stem cell biology, tumorigenesis, and metastasis
in vivo.Cell 154, 311miR-22 Triggers Methylation-
Dependent Silencing of miR-200
The E-box-binding transcription factors
Zeb1 (also known as TCF8 and dEF1)
and Zeb2 (also known as ZFXH1B and
SMAD-interacting protein 1 [SIP1]) and
the miR-200 family members have beenshown to regulate EMT in multiple cancer types (Gregory et al.,
2008; Park et al., 2008; Peinado et al., 2007). Zeb1 and Zeb2
are key transcriptional repressors of E-cadherin, whereas the
miR-200 family is known as important regulators of both EMT
and mammary stem cell function through direct targeting of the
mRNA of both Zeb1/Zeb2 and Bmi1 (Iliopoulos et al., 2010;
Shimono et al., 2009). Strikingly, we found that miR-22 is able
to repress miR-200a and miR-200c expression, leading to
upregulation of Zeb1, Zeb2, and Bmi1 in both human breast
epithelial cells and mouse mammary epithelium prepared from
miR-22F/+;MMTV-Cre mice (Figures 1B, 4A–4C, and S1E and
S1I). Taken together, these data suggest that in mammary
epithelial cells miR-22 induces EMT and stemness by suppress-
ing the expression of miR-200 family.
Recent studies have likewise shown that CpG island hyperme-
thylation-mediated epigenetic silencing of the miR-200 family is
associated with upregulation of Zeb1/Zeb2 expression, EMT–324, July 18, 2013 ª2013 Elsevier Inc. 315
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Figure 4. miR-22 Regulates Epigenetic Inactivation of miR-200 and Directly Targets TET Methylcytosine Dioxygenases
(A and B) Real-time qPCR analysis of Zeb1/Zeb2 (A) or miR-200a/miR-200c (B) with RNAs from MCF-10A cells infected with the miR-22 expressing or empty
vector. The data are represented as mean ± SD from three independent experiments.
(C) Real-time qPCR analysis of miR-200a/miR-200c with RNAs obtained from miR-22F/+;MMTV-Cre mice and littermate controls. The data are represented as
mean ± SD (n = 3).
(legend continued on next page)
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and metastasis (Davalos et al., 2012; Neves et al., 2010; Vrba
et al., 2010). We therefore analyzed the promoter of mir-200
using the methyl-specific PCR (MSP) analysis and found that it
is indeed hypermethylated upon miR-22 overexpression (Fig-
ure 4D). Notably, treatment of these cells with a DNA-demethy-
lating agent, 50-aza-20-deoxycytidine (50-Aza), reversed the
effects of miR-22 and restored expression of miR-200 tran-
scripts (Figures 4E and S3A), suggesting that miR-22 may have
a functional role in the dynamic control of DNA methylation.
The recent identification of 5hmC as a novel demethylation
standpoint and a biomarker associated with tumor development
(Haffner et al., 2011; Nestor et al., 2012; Song et al., 2011; Wu
and Zhang, 2010; Yang et al., 2013) prompted us to hypothesize
that miR-22may antagonizemiR-200 transcription by controlling
5hmC levels on genomic DNA. Indeed, miR-22 overexpression
significantly depleted 5hmC levels within mir-200 promoter
CpG islands (Figure 4F). Taken together, these results suggest
that miR-22 suppresses the demethylation of the promoter
within the mir-200 gene and represses its expression, leading
to upregulation of its cognate targets.
miR-22Regulates the Level of 5-Hydroxymethylcytosine
by Directly Targeting TET Family Members
miR-22 has been shown to exert growth-suppressive functions
in vitro in some cancer cell lines (Ling et al., 2012; Pandey and
Picard, 2009); our investigation, however, revealed an unex-
pected oncogenic function for miR-22, which we further
explored in order to identify the targets of its oncogenic activity
in breast cancer. Potential molecular targets of miR-22 were
predicted by prediction algorithms including TargetScan
6.0 (http://www.targetscan.org) (Lewis et al., 2005), microRNA.
org (http://www.microrna.org) (Betel et al., 2008) and miRBase
(http://www.mirbase.org) (Griffiths-Jones et al., 2006). Among
the potential targets, we focused on the TET family—enzymes
that contribute to DNA demethylation by converting 5mC to
5hmC and have recently been implicated in epigenetic reprog-
ramming, cellular differentiation and cancer (Ito et al., 2010; Ko
et al., 2010; Langemeijer et al., 2009; Tahiliani et al., 2009) (Fig-
ures 4G and S3B). Remarkably, real-time qPCR and western(D) Methylation-specific PCR analysis ofmir-200c CpG islands with genomic DNA
(E) Restored miR-200c expression upon treatment with DNA demethylating agen
expressing vector. The data are represented as mean ± SD (n = 3).
(F) GlucMS-qPCR analysis of CpG islands within the mir-200c promoter region
infected with the miR-22-expressing vector. The data are represented as mean
(G) Representative seed sequences for miR-22 on the TET family: 7 base pairs (red
and seed match sequences of miR-22 within 30 UTR of human and mouse TET2
(H) Total RNAs isolated from primary mammary epithelial cells of miR-22F/+;MM
Tet2, and Tet3 mRNA. The data are represented as mean ± SD (n = 3).
(I) Total RNAs isolated from MCF-10A cells transfected with the inhibitor (decoy)
The data are represented as mean ± SD (n = 3).
(J) Luciferase assay of the luciferase gene linked to the 30 UTR of TET2. HEK293
reporter plasmids encoding wild-type (left) or mutated (right) 30 UTR sequences o
data are represented as mean ± SD (n = 3).
(K) Genomic DNA purified from HEK293 cells expressing control miRNA, miR-22,
measured by using a dot blot assay with anti-5hmC antibody and normalized by
(right). The data are represented as mean ± SD (n = 3).
(L) 5hmC- and DAPI-stained sections of the duct of mammary glands isolated f
100 mm. The arrows indicate the cells with strong 5hmC-positive signals.
See Figure S3.blot analyses revealed that miR-22 expression in MCF-10A
and human embryonic kidney (HEK) 293 cells, and in vivo in
the mammary glands of miR-22F/+;MMTV-Cre mice, leads to a
robust downregulation of TET family members (Figures 4H and
S1I, S3C and S3D). This was in agreement with the high degree
of cross species conservations of the predicted miR-22 micro-
RNA recognition elements (MREs) in TET family members
(Figures 4G and S3B). In contrast, inhibiting miR-22 by using
antisense oligonucleotides resulted in a significant elevation in
expression of TET family members (Figure 4I). Notably, a lucif-
erase reporter assay performed using the 30 UTR region of
TET2 (which, however, contains the miR-22 MREs also identical
within the 30 UTR of TET1, TET2, and TET3) (Figure 4G), and
its mutant version in the miR-22 MREs, demonstrated that
miR-22-mediated repression of TET is due to a direct interac-
tion between miR-22 and the TET genes (Figures 4J and S3E
and S3F).
A reduction in the levels of 5hmC has been recently observed
in cancer cells, along with inactivation of TET proteins (Haffner
et al., 2011; Nestor et al., 2012; Yang et al., 2013). We therefore
next assessed whether miR-22 can remodel the epigenetic
landscape by altering 5hmC levels in the genome through the
TET family. Dot blot assay and immunofluorescence analysis
with anti-5hmC antibodies revealed that miR-22 over-
expression is indeed able to reduce global 5hmC levels
(Figures 4K and S3G). More importantly, 5hmC levels were
drastically reduced in vivo in the mammary glands of miR-
22F/+;MMTV-Cre mice compared to littermate controls (Fig-
ure 4L). Taken together, these data suggest that changes in
this important epigenetic mark (e.g., 5hmC) may contribute
to the ability of miR-22 to impact on EMT, stemness and
metastasis.
Downregulation of miR-22 or the TET Family Members
Alters EMT, Stemness, and miR-200 Expression Levels
Our observations that ectopic expression of miR-22 promotes
EMT and represses TET and miR-200 in turn prompted us to
investigate whether miR-22 inhibition could suppress EMT,
leading to the elevation of expression of TET and miR-200. Tos purified from the indicated cells infected with the miR-22-expressing vector.
t 50-aza-20-deoxycytidine (50-Aza) in MCF-10A cells infected with the miR-22-
s specifically enriched for 5-hydroxymethylcytosine (5hmC) in MCF-10A cells
± SD (n = 3).
-colored) and 8 base pairs (blue-colored) on human andmouse TET family (top)
b as an example (bottom) are shown.
TV-Cre mice or littermate controls were subjected to real-time qPCR for Tet1,
of miR-22 were subjected to real-time qPCR for TET1, TET2, and TET3 mRNA.
cells were transiently transfected with a combination of pGL3 firefly luciferase
f human TET2b, miR-22, and a Renilla luciferase reporter for normalization. The
or TET2 siRNA was denatured and neutralized. Global 5hmC levels were then
methylene blue staining (left). The resulting 5hmC levels were also quantified
rom 7-week-old miR-22F/+;MMTV-Cre mice or littermate controls. Scale bar,
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Figure 5. Loss of miR-22 or TET Family Members Alters EMT, Stemness, and miR-200 Levels
(A) Cell lysates from LM2 cells infected with the control or miR-22 sponge were subjected to western blot analysis for the indicated proteins. PTEN protein was
used as a verified miR-22 target to show the efficacy of the miR-22 sponge in this analysis.
(B) LM2 cells infected with the miR-22 sponge were subjected to the cell migration (top) and invasion assay (bottom). Representative fields of the cells are shown
(left). Scale bars, 100 mm. Themigrated or invaded cells were also quantified (right). The data are represented asmean ± SD from three independent experiments.
(C) Real-time qPCR analysis of miR-200a/miR-200c with RNAs from LM2 cells infected with the miR-22 sponge. The data are represented as mean ± SD
(n = 3).
(legend continued on next page)
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address this possibility, we first evaluated miR-22 expression
rates in a large panel of breast cancer cells (including two nontu-
morigenic cells and seven ERa-positive and four ERa-negative
breast cancer cell lines); we then focused on LM2 cells as these
cells are highly metastatic and express a substantial amount of
miR-22 compared to other breast cancer cell lines (Figure S4A).
Next, we generated a retroviral polymerase II sponge by inserting
miR-22-binding sites, arrayed in tandem, into the 30 UTR of a
reporter gene encoding destabilizedGFP driven by theCMVpro-
moter (Figure S4B, top; Ebert et al., 2007). ThesemiR-22-binding
sites were perfectly complementary in the seed region, with a
bulge at positions 9–12 to prevent degradation of the sponge
RNA (Figure S4B, bottom). To examine the effects of miR-22
inhibition on EMT and miR-200 expression, we infected LM2
cells expressing abundant endogenous miR-22 with either the
CXCR4 control sponge plasmid (Cont. Sponge) or the sponge
plasmid complementary to miR-22 (miR-22 Sponge). Impor-
tantly, inhibition of miR-22 by the miR-22 sponge in LM2 cells
led to a reduction of metastatic phenotypes, as measured
by cell migration, invasion abilities and the expression of the
mesenchymal marker vimentin accompanied with elevation in
the levels of TET proteins (Figures 5A and 5B). Noticeably, inhib-
iting miR-22 by the miR-22 sponge also resulted in a significant
increase in the levels of miR-200 family members (Figure 5C). In
agreement with these in vitro observations, miR-22 decoying by
the miR-22 sponge drastically inhibited in vivo breast cancer
metastases to the lung in xenograft models established with
LM2 cells (Figures 5D and 5E).
Next, we investigated whether repression of TET family mem-
bers could account for the phenotypes caused by miR-22 over-
expression in EMT, stemness and metastasis. To this end, we
knocked down TET2 or TET3 in MCF-10A cells by using RNA
interference (RNAi) and analyzed the resulting effect on EMT
and stemness. Notably, knockdown of TET2 or TET3 by RNAi
enhanced epithelial cell migration, EMT, and mammosphere
formation, suggesting that repression of the TET family creates
phenotypes similar to those of miR-22 overexpression (Figures
5F, 5G, 5J, 5K and S4C–S4E). Furthermore, downregulation of
TET2 or TET3 resulted in a reduction in 5hmC levels at the mir-
200 promoter and caused a decline in miR-200 expression
(Figures 5H, 5I, 5L and 5M).
To further understand the metastasis-suppression function of
TET family members in vivo, we analyzed lung metastases
in MCF-7 xenograft models with stable knockdown of TET2.
Importantly, mice that received the orthotopic implantation of
TET2-depleted MCF-7 cells displayed a suggestive lung metas-
tasis (Figure S4F). Taken together, these data indicate that TET(D and E) H&E-stained sections of primary mammary tumors (left), or H&E-stained
injection of control- or miR-22 sponge-infected LM2 cells (right) (D). Scale bars
orthotopic injection is also shown (E).
(F and J) MCF-10A cells infected with the lentiviral vector expressing TET2 (F) or TE
were then quantified. The data are represented as mean ± SD (n = 3).
(G and K) Cell lysates from MCF-10A cells expressing TET2 (G) or TET3 (K) shRN
(H and L) Real-time qPCR analysis of miR-200c with RNAs from MCF-10A cells ex
(n = 3).
(I and M) GlucMS-qPCR analysis of CpG islands within the mir-200c promoter re
TET3 (M) shRNA. The data are represented as mean ± SD (n = 3).
See Figures S4A–S4F.family members inhibit EMT, stemness, and tumor metastasis
and positively regulate miR-200 expression.
miR-22-Induced EMT, Stemness, and Repression of
miR-200 Rely on Its Ability to Silence TET Family
Members
To finally determine whether TET family members directly
contribute to miR-22 function, we ectopically expressed TET2
or TET3 in miR-22-overexpressing MCF-10A cells and then
analyzed epithelial cell migration, EMT, and stemness. Impor-
tantly, the exogenously expressed TET proteins significantly
diminished the cell migration, EMT, and mammosphere forma-
tion elicited by miR-22 overexpression (Figures 6A–6C and
6F–6H). Furthermore, silencing the expression of global 5hmC
and miR-200 caused by miR-22 was rescued by the ectopic
expression of TET2 or TET3 (Figures 6D, 6E, 6I, 6J and S4G),
suggesting that TET proteins are very likely to be major factors
in reliable miR-22 function in suppression of demethylation of
miR-200.
To further evaluate whether the invasion-suppression capacity
of miR-22 inhibition directly relates to the TET family, we
knocked down TET2 or TET3 by RNAi in LM2 metastatic breast
cancer cell line after applying the miR-22 sponge (Figure 6K).
Noticeably, the dramatic reduction in cell invasion caused by
miR-22 inhibition was overcome by knockdown of TET proteins
(Figures 6L and S4H). Taken together, these data suggest that
TET family members are the major players responsible for
miR-22 function in EMT, stemness and repression of miR-200.
miR-22 Overexpression Correlates with Poor Clinical
Outcomes and Silencing of the TET-miR-200 Axis in
Patients
Finally, we sought to determine whether our observations could
be verified in human breast cancer patients. Indeed, we
observed a high expression rate of miR-22 in non-triple-negative
breast cancer (non-TNBC) subtypes of breast cancer when
compared to normal breast tissue (Figures 7A and S5A andBuffa
et al., 2011; Enerly et al., 2011).
To further evaluate the relationship between miR-22 overex-
pression and tumor aggressiveness in non-TNBC patients, we
analyzed miR-22 levels in breast cancer tissue samples positive
for ERa by real-time qPCR, using RNU6B as an internal control.
Critically, the breast cancer patients found to have high expres-
sion levels of miR-22 had high-grade tumors of an advanced
stage (p = 0.047; Figure 7B), and poor survival rates as compared
to the patients with low miR-22 expression levels (p = 0.022,
Figure 7C).and Ki67-stained sections of lungs isolated frommice that received orthotopic
, 100 mm. The incidence of metastases to the lung in mice at 10 weeks after
T3 (J) shRNAwere subjected to the cell migration assay and themigrated cells
A were subjected to western blot analysis for the indicated proteins.
pressing TET2 (H) or TET3 (L) shRNA. The data are represented as mean ± SD
gions specifically enriched for 5hmC in MCF-10A cells expressing TET2 (I) or
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Figure 6. TET Family Members Are
Required for miR-22-Induced EMT, Stem-
ness, and miR-200 Repression
(A and F) MCF-10A cells infected with a combi-
nation of the miR-22-, (A) TET2b-, and (F) TET3-
expressing vector were subjected to the cell
migration assay. Representative fields of the
migrated cells are shown (left). Scale bars, 100 mm.
The migrated cells were also quantified (right). The
data are represented as mean ± SD from three
independent experiments.
(B and G) Cell lysates from MCF-10A cells ex-
pressing a combination of the miR-22, TET2b (B)
and TET3 (G) were subjected to western blot
analysis for the indicated proteins. Asterisk
indicates nonspecific band.
(C and H) Mammospheres derived from MCF-10A
cells expressing a combination of the miR-22,
TET2b (C) and TET3 (H) were measured. The
number of mammospheres per 1,000-plated cells
in each culture was then quantified. The data are
represented as mean ± SD (n = 3).
(Dand I)GenomicDNApurified fromMCF-10Acells
expressing a combination of themiR-22, TET2b (D)
and TET3 (I) was denatured and neutralized. Global
5hmC levels were then measured by a dot blot
assay using anti-5hmC antibody.
(E and J) Real-time qPCR analysis of miR-200c
with RNAs from MCF-10A cells expressing a
combination of the miR-22, TET2b (E), and TET3
(J). The data are represented as mean ± SD (n = 3).
(K and L) LM2 cells infected with a combination of
the control and miR-22 sponge and the TET2 or
TET3 shRNA-expressing vector were subjected to
western blot analysis for the indicated proteins (K)
and the cell invasion assay (L). Asterisk indicates
nonspecific band. The data are represented as
mean ± SD (n = 3).
See Figures S4G and S4H.Interestingly, in this analysis miR-22 was also found to be
significantly coexpressed with genes involved in breast cancer
metastasis, including those that encodematrixmetalloproteases
11 and 1 (Pearson r = 0.536 and 0.392, respectively), cathepsin B
(0.500), integrin a11 (0.425), TGF-bR-associated protein (0.416),
collagen Xa1 (0.411), TGF-b1 (0.407), fibronectin 1 (0.403), and
laminin a5 (0.399) (Bierie and Moses, 2006; McCarthy et al.,
1985; Melisi et al., 2008; Radisky and Radisky, 2010; Vuoristo
et al., 2007; Withana et al., 2012) (Table S1). This observation
also supports the notion that in breast cancer miR-22 is prome-
tastatic and contributes to aggressive disease.
More importantly, and consistent with our functional studies,
miR-22 expression was directly anticorrelated with the expres-
sion of TET1 and TET2 in human breast cancer patients; in addi-
tion, a statistically significant anticorrelation between miR-22320 Cell 154, 311–324, July 18, 2013 ª2013 Elsevier Inc.and TET3 was also observed but only in
the non-TNBC breast cancer subset (Fig-
ure 7D and p = 0.014, Figure S5B).
Lastly, we examined whether downre-
gulation of TET family members by miR-
22 can explain its effects on miR-200sexpression in human breast cancer tissues. In support of this
possibility, we found a clear correlation between the expression
of TET1 and TET2 and miR-200s in human breast cancer
patients; although a correlation was also found between TET3
and miR-200s, this was not statistically significant (Figures 7E
and S5C). Taken together, these results reveal miR-22 as a
crucial and unexpected switch for a metastatic phenotype of
breast cancer via repression of TET family members/miR-200s.
DISCUSSION
Collectively, our findings have allowed us to reach a number of
important conclusions:
miR-22 promotes EMT and tumor invasion and metastasis.
Using in vivo miR-22 transgenic mouse models, we further
A B C
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Figure 7. miR-22 Overexpression Corre-
lates with Poor Clinical Outcomes and
Silencing of the TET-miR-200 Axis in
Patients
(A) miR-22 expression profiling was analyzed from
a previously published Illumina Human RefSeq-8
and miRNAv1 array data set (superSeries
GSE22220). Breast tumors were classified by
molecular subtypes, estrogen receptor (ER), pro-
gesterone receptor (PR), ERBB2 (HER-2), and
epithelial clusters.
(B) miR-22 expression was analyzed by using a
real-time qPCR with RNAs from human breast
cancer patient samples. Tumor grade was deter-
mined by the parameters, ER, PR, ERBB2 (HER-2),
and epithelial clusters. HG, ER-positive high-grade
tumors; LG, ER-positive low-grade tumors.
(C) TNBC patient samples were subdivided into
two groups according to low and high expression
of miR-22 with median split of all samples. A
Kaplan-Meier plot representing the disease-free
survival of patients was stratified.
(D) Anticorrelation between miR-22 and TET family
expressions was analyzed using a real-time qPCR
with RNAs from breast cancer patient samples.
(E) Coexpression analysis of TET family and miR-
200a/miR-200c was analyzed by using a real-time
qPCR with RNAs from breast cancer patient
samples.
(F) Proposed model of the role of miR-22 for EMT,
stemness and metastasis through epigenetic inac-
tivation of miR-200 by directly targeting the TET
family. miR-22 decreases the level of 5hmC by
negatively regulating TET family, followed by
epigenetic inactivation of miR-200 due to the
reduced 5hmC levels. Ultimately, dysfunction of
miR-200 triggers EMT and stemness, which in turn
increasesmammary tumorigenesisandmetastasis.
See Figure S5 and Table S1.show miR-22 can promote lobuloalveolar structures and MSCs
stemness and impart mammary tumor development and inva-
sive and metastatic properties. Other studies have demon-
strated that miR-22 could play a role in the pathogenesis of
breast cancer by interacting with the 30 UTR region of ERa and
regulating ERa expression (Pandey and Picard, 2009; Xiong
et al., 2010). However, we and others found no effect of miR-
22 on expression of ERa in either clinical samples or miR-
22F/+;MMTV-Cre transgenic animals (Figures 1H and S1I and
Yoshimoto et al., 2011).
The findings presented here are coherent with a proto-onco-
genic role for miR-22, and with previous findings implicating
miR-22 in the regulation of PTEN (phosphatase and tensin
homolog deleted on chromosome 10) tumor suppressor (Poli-
seno et al., 2010). Although inactivation of PTEN may contributeCell 154, 311–to the role of miR-22 in breast cancer
initiation, it has little effect on EMT in the
various tissues including breast (S.J.S.
and P.P.P., unpublished data andMulhol-
land et al., 2012; Shorning et al., 2011;
Wang et al., 2012). Moreover, unlikemiR-22F/+;MMTV-Cre transgenic mice, the 5hmC levels in pre-
cancerous mammary glands of Pten mutant mice were not
appreciably different from littermate controls, indicating that
miR-22 functions as an epigenetic modifier and EMT promoter
independently of its ability to target PTEN (Figure S3H).
We propose a mechanism and a model for antagonistic
miRNA crosstalks whereby one miRNA (e.g., miR-22) can sup-
press the expression of another miRNA (e.g., miR-200) via direct
targeting of chromatin remodeling enzymes such as TET family
members, which in this specific example in turn leads to the
hypermethylation of the mir-200 promoter and induction of
EMT and stemness (Figure 7F). Indeed, aberrant DNA methyl-
ation of CpG islands from mir-200 family appears to be closely
linked to their silencing during EMT and metastasis, whereas
epigenetic modifier drugs such as 5-aza-20-deoxycytidine can324, July 18, 2013 ª2013 Elsevier Inc. 321
reactivate miR-200 family expression, indicating that epigenetic
mechanisms play a functional role for controlling the expression
of this family in cancer (Davalos et al., 2012; Li et al., 2010; Vrba
et al., 2010).
TET2-inactivating deletion andmutations have been observed
in hematopoietic malignancies (Shih et al., 2012), and yet to date,
whether TET family members play a role in solid tumors and
metastasis remained an open question. Our results, i.e., that in-
hibition of TET proteins triggers a similar phenotype as miR-22
overexpression in EMT and stemness and that the phenotypes
caused by miR-22 are abolished by ectopic expression of TET
proteins, demonstrate that the TET family acts as a major target
in mediating the function of miR-22 in breast cancer and metas-
tasis. In turn, these data suggest that the functional and concom-
itant loss of TET family members may be extremely relevant to
the pathogenesis of solid tumors.
It has also been recently reported that mutations of the isoci-
trate dehydrogenase genes IDH1 and IDH2 can lead to the aber-
rant production of 2-hydroxyglutarate (2-HG), a metabolite that
inhibits TET2 enzymatic activity, resulting in a hypermethylated
promoter phenotype in acute myeloid leukemia (AML) tumors
carrying IDH1/2 mutations (Figueroa et al., 2010), further high-
lighting a possible critical role for TET family members in the
epigenetic deregulation observed in many cancers. Importantly,
beside mutations specifically targeting TET2 or IDH1/2 genes,
our results now reveal an additional and global silencing mech-
anism of the whole TET family by miR-22, which can block
the 5mC-to-5hmC conversion and thus DNA demethylation.
The fact that miR-22 can target multiple TET family members
at once explains on the one hand its powerful effects on the
global epigenetic landscape but also its potent proto-oncogenic
role in multiple tissues (Song et al., 2013).
Our findings not only help at further defining the molecular
basis of tumor metastasis, but also have important implications
for the diagnosis, prognosis and treatment of cancer. As miR-22
triggers EMT and ametastatic phenotype and its overexpression
correlates with poor clinical outcomes in patients, it might be uti-
lized as a useful biomarker to identify metastatic forms of breast
cancer. Critically, our results that inhibitingmiR-22 by themiR-22
sponge in highly metastatic cells leads to a reduction of metasta-
tic phenotypes, as well as an elevation of the expression of TET
and miR-200, provide a rationale for the therapeutic targeting of
miR-22 (e.g., by using the LNA [locked nucleic acid] miR-22
inhibitors) in order to prevent EMT and metastatic phenotypes.
EXPERIMENTAL PROCEDURES
Mice
Cre-inducible miR-22 expression construct was generated in which a LoxP-
flanked transcriptional STOP element was inserted between a CAGGS pro-
moter and mir-22. This construct was targeted into the mouse Collagen A1
locus using Flp recombinase-mediated genomic integration. Mouse embry-
onic stem cells carrying a single copy of the mir-22 STOP construct were
identified by resistance to the antibiotic marker hygromycin and Southern blot-
ting. Selected clones were injected into blastocysts to generate pups. To
generate MMTV-Cre;miR-22F/+ mice, miR-22F/+ mice were bred to MMTV-
Cre transgenic strain (Jackson Laboratory). To generate MMTV-PyVT;miR-
22F/+;MMTV-Cre or MMTV-neu;miR-22F/+;MMTV-Cre compound transgenic
mice, MMTV-miR-22F/+ mice were crossed with MMTV-PyVT or MMTV-neu
(unactivated) transgenic mice, respectively (Jackson Laboratory). Animal322 Cell 154, 311–324, July 18, 2013 ª2013 Elsevier Inc.experiments were approved by the Animal Care Committee of Harvard
Medical School/Beth Israel Deaconess Medical Center. The sources of
primers used for genotyping are described in the Extended Experimental
Procedures.
Immunohistochemistry
Tissues were fixed in 4% Paraformaldehyde and wash with PBS and transfer
to 70% ethanol and then embedded in paraffin in accordance with standard
procedures. Sections were stained for hematoxylin and eosin (H&E), Ki-67
(Novocastra), GFP (Cell Signaling), MECA-32 (BioLegend), ERa (Abcam),
TTF1 (DAKO), Cytokeratin-8 (Abcam), and cytokeratin-14 (Novus Biologicals).
5-hydroxymethylcytosine-specific antibody (Active Motif) was applied at
1:1,000 dilutions for tissue immunofluorescence analysis.
Orthotopic Injection
Four-week-old female Nu/Nu immunodeficient mice (Jackson Laboratory)
were used for surgery. Mice were anaesthetized with isoflurane. The skin
was incised and the endogenous mammary epithelial was removed from the
4th fat pad from the nipple connect to the part distal of the mammary lymph
node by electrocauterization before the implantation. Then, MCF-7 or LM2
cells (1 3 105) in 50 ml growth medium/matrigel (BD Biosciences) were
injected into the rest of mammary fat pad (n = 6). For an E2 supplementation,
mice have been given injections of b-estradiol (Sigma) dissolved in pure ses-
ame oil (0.1 mg per 0.05 ml sesame oil per mouse, subcutaneously) 1 day
before orthotopic injection of MCF-7 cells, and then at weekly intervals until
the conclusion of the experiment.
Whole-Mount Staining
The fourth inguinal glands were dissected at the indicated ages and were
spread on a glass slide. After fixation with acidic alcohol for 2 hr, the tissues
were hydrated and stained in Carmine alum for overnight as described (Jack-
son-Fisher et al., 2004). Samples were then dehydrated, cleared with xylene,
and mounted.
Mouse Mammary Stem Cell Analysis
Mammary glands were dissected from 7-week-old female mice. After
mechanical dissociation, the cells were prepared and analyzed. All reagents
were from StemCell Technologies. Cells were stained with biotinylated
anti-CD45, -Ter119, -CD31, and -CD140a (eBioscience) for 1 hr on ice. After
extensive washing with PBS/2%FBS, cells were stained with anti-CD24-
FITC, -CD29-PE, -CD49f and streptavidin-APC-eBluor 780 (eBioscience) for
45 min on ice. For a flow cytometric analysis, DAPI-negative cells were gated
and analyzed. Mammary stem cell transplantation assay was performed as
previously described (Shimono et al., 2009).
Human Patient Samples
Human patient samples were analyzed as described in detail in the Extended
Experimental Procedures. This study was approved by the institutional review
boards of Dana Farber/Harvard Cancer Center.
Glucosylation of Genomic 5hmC Followed by Methylation-Sensitive
qPCR
Genomic DNAwas treatedwith T4 Phage b-glucosyltransferase (T4-BGT, New
England Biolabs) according to the manufacturer’s instruction. Glucosylated
genomic DNA (100 ng) was digested with 10 U of HpaII, MspI or no enzyme
(mock digestion) at 37C overnight, followed by inactivation for 20 min at
80C. The HpaII- or MspI-resistant fraction was quantified by qPCR using
primers designed around at least one HpaII/MspI site, and normalizing to the
mock digestion control. Resistance to MspI directly translates into percentage
of 5hmC, whereas 5mC levels were obtained by subtracting the 5hmC contri-
bution from the total HpaII resistance.
Methylation-Specific PCR
DNA methylation status was examined by the methylation-specific PCR with
genomic DNA treated with sodium bisulfite using the EZ DNA Methylation-
Direct kit (Zymo Research). Primers as described were used (Davalos et al.,
2012).
Statistical Analysis
Student’s t test was utilized to determine statistical significance unless other-
wise specified. p values lower than 0.05 were considered statistically
significant.
The details of plasmids, cell culture and transfection, immunocytochemistry,
real-time quantitative PCR, luciferase reporter assay, dot and western blot
analyses and cell migration and invasion assay are also described in the
Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and one table and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2013.06.026.
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